| 86R1825 KKR-D  
---|---  
|  By: Blanco | H.B. No. 697  
---  
|  A BILL TO BE ENTITLED  
|  AN ACT  
| relating to required prescription drug cost and rebate reporting;  
| authorizing a civil penalty.  
|  BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:  
|  SECTION 1. Section 430.001, Health and Safety Code, is  
| amended by amending Subdivision (1) and adding Subdivision (1-a) to  
| read as follows:  
|  (1) _"Commission"_ ___means the Health and Human Services_  
| _Commission._  
|  _(1-a)_ "Commissioner" means the commissioner of state  
| health services.  
|  SECTION 2. Subchapter E, Chapter 431, Health and Safety  
| Code, is amended by adding Sections 431.1165 and 431.1166 to read as  
| follows:  
|  _Sec._ ___431.1165._ _____PRESCRIPTION DRUG MANUFACTURER COST_  
| _REPORTING; CIVIL PENALTY. (a)_ ___In this section:_  
|  _(1)_ _____"Manufacturer" means a person licensed or approved_  
| _by the United States Food and Drug Administration to engage in the_  
| _manufacture of drugs or devices, consistent with the federal_  
| _agency's definition of "manufacturer" under the agency's_  
| _regulations and guidances implementing the Prescription Drug_  
| _Marketing Act of 1987 (Pub. L. No._ ___100-293)._ _____The term does not_  
| _include a pharmacist engaged in compounding that is within the_  
| _practice of pharmacy and is in accordance with a prescription drug_  
| _order or initiative from a practitioner for a patient or_  
| _prepackaging that complies with Section 562.154, Occupations Code._  
|  _(2)_ _____"Prescription drug" has the meaning assigned by 21_  
| _C.F.R. Section 203.3._  
|  _(b)_ _____Not later than February 1 of each year, the commission_  
| _shall:_  
|  _(1)_ _____identify the prescription drugs and the wholesale_  
| _price for each drug the commission determines is essential to_  
| _treating diabetes in this state, including insulin and biguanides;_  
|  _(2)_ _____identify the prescription drugs described by_  
| _Subdivision (1) for which the wholesale price has increased in an_  
| _amount equal to or greater than:_  
|  _(A)_ _____the percentage of price increase in the_  
| _medical care component of the consumer price index as published by_  
| _the Bureau of Labor Statistics of the United States Department of_  
| _Labor during the preceding calendar year; or_  
|  _(B)_ _____two times the percentage of price increase in_  
| _the medical care component of the consumer price index as published_  
| _by the Bureau of Labor Statistics of the United States Department of_  
| _Labor during the preceding two calendar years; and_  
|  _(3)_ _____post the information compiled under Subdivisions_  
| _(1) and (2) on the commission's Internet website._  
|  _(c)_ _____Not later than August 1 of each year, a manufacturer_  
| _shall submit to the commission, in the manner and form prescribed by_  
| _the executive commissioner, a report for each prescription drug_  
| _identified under Subsection (b) that is manufactured by the_  
| _manufacturer and available for sale in this state._  
|  _(d)_ _____For each prescription drug identified under Subsection_  
| _(b)(1) and included in the report under Subsection (c), the_  
| _manufacturer, for the preceding calendar year, shall provide:_  
|  _(1)_ _____the cost incurred by the manufacturer in producing_  
| _the drug;_  
|  _(2) the wholesale price of the drug;_  
|  _(3)_ _____a history of any increases in the wholesale price_  
| _of the drug for the preceding five years, including the amount of_  
| _each increase expressed as a percentage of the total wholesale_  
| _price of the drug, the month and year the price increase took_  
| _effect, and any explanation for the price increase;_  
|  _(4)_ _____the profit derived from the sale of the drug,_  
| _expressed as an amount and as a percentage of the manufacturer's_  
| _total profit from all prescription drugs sold by the manufacturer;_  
|  _(5)_ _____the administrative, marketing, and advertising_  
| _costs of promoting the drug;_  
|  _(6)_ _____the cost to the manufacturer of coupons provided_  
| _directly to consumers to assist consumers in paying copayments and_  
| _the value of the coupons redeemed;_  
|  _(7)_ _____the cost to the manufacturer of programs designed_  
| _to assist consumers in paying copayments for the drug;_  
|  _(8)_ _____the amount of financial assistance provided for_  
| _the drug by the manufacturer through patient prescription_  
| _assistance programs; and_  
|  _(9)_ _____the aggregate amount of rebates paid to pharmacy_  
| _benefit managers, as defined by Section 4151.151, Insurance Code,_  
| _for sales of the drug in this state._  
|  _(e)_ _____For each prescription drug identified under Subsection_  
| _(b)(2) and included in the report under Subsection (c), the_  
| _manufacturer, for the preceding calendar year, shall provide_  
| _information that justifies the increase in the wholesale price,_  
| _including:_  
|  _(1)_ _____the factors contributing to the wholesale price_  
| _increase;_  
|  _(2)_ _____the percentage of the total wholesale price_  
| _increase attributable to each factor; and_  
|  _(3)_ _____an explanation of the role of each factor in_  
| _contributing to the wholesale price increase._  
|  _(f)_ _____Not later than December 1 of each year, the commission_  
| _shall prepare and post on the commission's Internet website a_  
| _report outlining the information provided by a manufacturer under_  
| _this section._ ___The report may not include information likely to_  
| _compromise the financial, competitive, or proprietary nature of the_  
| _information._  
|  _(g)_ _____Information provided by a manufacturer to the_  
| _commission under this section is confidential and is not subject to_  
| _disclosure under Chapter 552, Government Code._  
|  _(h)_ _____A manufacturer that does not submit the report required_  
| _by Subsection (c) is liable to the state for a civil penalty of not_  
| _more than $5,000 for each violation._ ___The commission may waive the_  
| _civil penalty if a manufacturer provides good cause for the_  
| _manufacturer's failure to submit the report._ ___Each failure to_  
| _provide information to the commission is a separate violation and_  
| _each day of continuing violation constitutes a separate violation._ __  
| _The attorney general at the request of the commission may bring suit_  
| _to provide for injunctive relief or to recover a civil penalty, or_  
| _both._ ___The attorney general may recover court costs and reasonable_  
| _attorney's fees._  
|  _Sec._ ___431.1166._ _____PHARMACY BENEFIT MANAGER PRESCRIPTION DRUG_  
| _REBATE REPORTING. (a)_ ___In this section:_  
|  _(1)_ _____"Manufacturer" means a person licensed or approved_  
| _by the United States Food and Drug Administration to engage in the_  
| _manufacture of drugs or devices, consistent with the federal_  
| _agency's definition of "manufacturer" under the agency's_  
| _regulations and guidances implementing the Prescription Drug_  
| _Marketing Act of 1987 (Pub. L. No._ ___100-293)._ _____The term does not_  
| _include a pharmacist engaged in compounding that is within the_  
| _practice of pharmacy and is in accordance with a prescription drug_  
| _order or initiative from a practitioner for a patient or_  
| _prepackaging that complies with Section 562.154, Occupations Code._  
|  _(2)_ _____"Pharmacy benefit manager"_ ___has the meaning_  
| _assigned by Section 4151.151, Insurance Code._  
|  _(3)_ _____"Prescription drug" has the meaning assigned by 21_  
| _C.F.R. Section 203.3._  
|  _(b)_ _____Not later than August 1 of each year, a pharmacy benefit_  
| _manager shall submit a report to the commission, in the manner and_  
| _form prescribed by the executive commissioner, regarding rebates_  
| _for each prescription drug identified under Section 431.1165(b)(1)_  
| _that is available for sale in this state._ ___The report must include:_  
|  _(1)_ _____the total amount of rebates the pharmacy benefit_  
| _manager negotiated with all manufacturers during the preceding_  
| _calendar year;_  
|  _(2)_ _____the amount of the rebates described in Subdivision_  
| _(1) that were retained by the pharmacy benefit manager; and_  
|  _(3)_ _____the amount of any rebates described in Subdivision_  
| _(1) that were negotiated for use by persons who receive_  
| _prescription drug benefits or assistance under Medicare or a state,_  
| _local, or federal public program._  
|  _(c)_ _____This section does not apply to prescription drug_  
| _benefits provided under a health care benefit plan established_  
| _under the Employee Retirement Income Security Act of 1974 (29_  
| _U.S.C. Section 1001 et seq.)._  
|  _(d)_ _____Not later than December 1 of each year, the commission_  
| _shall prepare and post on the commission's Internet website a_  
| _report outlining the information provided by a pharmacy benefit_  
| _manager under this section._ ___The report may not include information_  
| _that is likely to compromise the financial, competitive, or_  
| _proprietary nature of the information._  
|  _(e)_ _____Information provided by a pharmacy benefit manager to_  
| _the commission under this section is confidential and is not_  
| _subject to disclosure under Chapter 552, Government Code._  
|  SECTION 3. As soon as practicable after the effective date  
| of this Act, the executive commissioner of the Health and Human  
| Services Commission shall adopt rules necessary to implement  
| Sections 431.1165 and 431.1166, Health and Safety Code, as added by  
| this Act.  
|  SECTION 4. This Act takes effect September 1, 2019.

